Volume | 0 |
|
|||||
News | - |
Company Name | Etf Ticker Symbol | Market | Type |
---|---|---|---|
Kelly Strategic ETF Trust Residential & Apt Real Estate ETF | RESI | NYSE | Exchange Traded Fund |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
16.23 | 16.23 |
Trades | Volume | Avg Volume |
---|---|---|
0 | 0 | - |
Last Trade Time | Type | Quantity | Etf Price | Currency |
---|---|---|---|---|
- | 0 | 16.23 | USD |
Kelly Strategic ETF Trust Residential & Apt Real Estate ETF Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
811.50k | - | - | - | 15.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Kelly Strategic
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
RESI Historical
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a ¿passive management¿ investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified. |